In a focused ultrasound triage study including 180 patients with diabetes, a ≥7-day withdrawal of GLP-1 RAs reduced the rate of “risk stomach” scans to 5%, compared to 17% in those who continued therapy [30]. Here, GLP1R is linked to diabetes mellitus.